Analgesics News
-
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
Positive results confirm findings from prior studies evaluating the abuse potential of cebranopadol, further highlighting its potential as a safe and potent alternative to traditional opioids Registrational phase 3 clinical trials of cebranopadol in moderate to severe acute pain are on track to initiate in Q4 2023 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage ...
-
Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline
Thomas Englese, a 20+ year industry veteran with a track record of success at leading biopharmaceutical companies, joins as chief commercial officer Marc Lesnick, Ph.D., appointed as chief development officer, bringing more than 20 years of experience in multiple therapeutic areas Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological ...
-
Targeting Alternative Opioid Receptor Reduces Drug Side Effects
A new study published in Proceedings of the National Academy of Sciences (PNAS) indicates, “Delta opioid receptors have a built-in mechanism for pain relief and can be precisely targeted with drug-delivering nanoparticles, making them a promising target for treating chronic inammatory pain with fewer side eects.” Researchers used cells from humans and mice with inammatory bowel ...
-
Alfa Chemistry Enriches API Supply by Adding Lenalidomide, Parecoxib Sodium, and Rivaroxaban
As one of the leading chemical manufacturers and suppliers globally, Alfa Chemistry is well-prepared to provide a number of active pharmaceutical ingredients (APIs), such as donepezil and dexmedetomidine hydrochloride, for customers worldwide ranging from lab to commercial scale. Earlier this month, the company announced that three other APIs had been introduced for its global customers as well, ...
-
The future of rehabilitation
Congratulations to the ONWARD team for the incredible progress they are making in the field of neuroengineering! In recent days, numerous media have reported the news of a great advance for science, and especially for all those people with spinal cord injury and their medical and caregiver teams. The ONWARD team has developed an epidural electrical stimulation system using electrodes placed ...
-
Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone
Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was significantly less as compared to immediate release (IR) formulations of either tramadol or oxycodone, suggesting a lower potential for abuse versus traditional C-II and C-IV opioids A first-in-class investigational analgesic uniquely ...
-
Differences Between Spinal Blocks & Epidurals
The biggest difference between spinal blocks vs epidurals is their amount of pain relief: spinal blocks provide total pain relief, while epidurals provide partial pain relief. The reason for this difference is that the former is an anesthetic, while the latter is an analgesic—no sensation versus no pain. But pain elimination comes with a total lack of feeling in the lower body, due to ...
-
XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report a significant potential market opportunity for its oral dissolvable (“ODF”) biosensor screening tests for oral inflammation. Certain buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been recently associated ...
-
What to Expect for an Epidural Injection
Roughly 8% of U.S. adults suffer from persistent or chronic back pain. That’s around 65 million people who are prevented from engaging in daily activities. Many are forced to miss days of work due to injury. With rising healthcare costs, many back pain sufferers think that they are left without a real solution, until they try epidural injections. An epidural injection is the infusion of ...
-
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder: A Double-Blind, Randomized, Sham-Controlled Pilot Study in the journal, Brain Stimulation. The ...
-
Know your Pain Management Options During Labor
Expecting a baby is undoubtedly a life changing event, and there are many factors to consider along the way. The crescendo of the nine month journey is of course the act of giving birth itself, but a chief concern among expecting mothers is “how will I manage my labor pain?” There will definitely be some discomfort involved, but it can be difficult to anticipate how much. Mothers ...
-
Personalized Methadone Dispensing Device for Take-Homes Receives NIDA Grant
The National Institutes of Health (NIH) has awarded Berkshire Biomedical Awarded $266,000 to support continued development of an automated, at-home methadone administration system. Called the COPA system, the proprietary, hand-held drug dispensing device is meant to provide at-home methadone administration as part of treatment for opioid use disorder (OUD). The system delivers the liquid ...
-
Alfa Chemistry Launches Thiophenes as Heterocyclic Organic Compounds for Academic Research and Industrial Manufacturing
Extensively existing in nature, heterocyclic organic compounds are of paramount importance in medicinal chemistry, the discovery of novel drugs in particular. Fully aware of the market demand for such chemicals, Alfa Chemistry recently announced the launch of thiophenes, a type of heterocyclic compound comprehensively ranged for scientists and researchers worldwide dedicated to exploring the ...
-
Landmark Survey by Stagwell`s The Harris Poll Estimates More Than 72.3 Million U.S. Adults Suffer from Chronic Low Back Pain - Greater than Arthritis, Diabetes, or Heart Disease and with Debilitating Impact on Quality of Life
Significant Drop in Mobility Due to Chronic Low Back Pain (CLBP) Demonstrated in New Mobility Index, with Highest Drop Among Those in Their 50s Treatment is Deficient with 15% Currently Taking Opioids Despite CDC Guidelines Noting Inadequate Effectiveness and Inherent Risks Only 5% Utilizing Recommended Minimally Invasive Treatment Options The Harris Poll, a Stagwell (NASDAQ: STGW) ...
-
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment Over 142 million opioid prescriptions dispensed in the U.S. in 20201 More than 1.7 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers in 20161 BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a ...
-
Berkshire Biomedical Awarded NIH Research Grant to Support Continued Development of the COPA System for Automated at Home Methadone Administration
Berkshire Biomedical Corporation ("Berkshire" or "the Company"), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced that it has been awarded the first phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1R44DA057185-01) from the National Institutes of Health's (NIH) National ...
-
Saluda Medical Announces Robust Scientific Presence at 2022 International Neuromodulation Society (INS) World Congress
Key data highlights with the Evoke® System to include holistic composite treatment outcomes for disrupting the chronic pain cycle; opioid-sparing effects of therapy; real-world results; and cost-effectiveness compared to open-loop stimulation. Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an ...
-
Murphy Highlights Norwalk’s Biowave as “Innovator of the Month”
U.S. Senator Chris Murphy (D-Conn.) announced that BioWave, based in Norwalk, CT, has been named April’s “Innovator of the Month.” BioWave is a patented smarter pain blocking technology that provides immediate, deep, long lasting relief of severe pain. BioWave devices deliver therapeutic electrical signals through skin directly to pain nerves in deep tissue to prevent pain ...
-
Berkshire Biomedical, Developers of COPA, Recognizes National Prescription Drug Take Back Day
Berkshire Biomedical Corporation (“Berkshire” or “the Company”), focused on developing its proprietary, hand-held, automated personalized drug dispensing technology to enhance patient wellness, today announced its support and recognition of the DEA’s National Prescription Drug Take Back Day on April 30, 2022. As stated in the DEA’s release, the drug overdose ...
-
VeriSIM Life Awarded Federal Grant from National Institutes of Health for Substance Use Disorder Drug Discovery and Development
VeriSIM Life (VeriSIM), the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, announced today it has been awarded a $312,310 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to fund AI-driven development of medications for substance use disorder (SUD). VeriSIM and UF Scripps ...
By VeriSIM Life
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you